Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUNDSystemic administration of adeno-associated virus (AAV) can trigger life-threatening inflammatory responses, including thrombotic microangiopathy (TMA), acute kidney injury due to atypical hemolytic uremic syndrome-like complement activation, immune-mediated myocardial inflammation, and hepatic toxicity.METHODSWe describe the kinetics of immune activation following systemic AAV serotype 9 (AAV9) administration in 38 individuals following 2 distinct prophylactic immunomodulation regimens. Group 1 received corticosteroids and Group 2 received rituximab plus sirolimus in addition to steroids to prevent anti-AAV antibody formation.RESULTSGroup 1 participants had a rapid increase in immunoglobulin M (IgM) and IgG. Increase in D-dimer, decline in platelet count, and complement activation are indicative of TMA. All Group 1 participants demonstrated activation of both classical and alternative complement pathways, as indicated by depleted C4 and elevated soluble C5b-9, Ba, and Bb antigens. Group 2 patients did not have a significant change in IgM or IgG and had minimal complement activation.CONCLUSIONSThis study demonstrates that TMA in the setting of AAV gene therapy is antibody dependent (classical pathway) and amplified by the alternative complement pathway. Critical time points and interventions are identified to allow for management of immune-mediated events that impact the safety and efficacy of systemic gene therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, levels of complement proteins associated with classical (C3a, C4a, C5a) and alternative (Ba, Bb) pathways along with terminal complement complex SC5b-9 were found to be elevated in patients who only received corticosteroids.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical studies in patients with Duchenne muscular dystrophy (DMD), where seronegative patients were administered with high dose AAV, suggest that IgM formation could still cause significant immunotoxicities.88,89”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Patients receiving only corticosteroids had increased levels of IgM and IgG on days 5 and 7, respectively.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Salabarria et al. evaluated the kinetics and effects of immune modulation on complement activation in groups of patients who received high systemic doses of AAV989.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
In the citing paper
“Based on these findings, the authors proposed that in humans, the classical pathway is critical for the initiation of complement activation and the occurrence of associated pathologies/toxicities following high-dose systemic delivery of AAV, whereas the alternative pathway may serve as an amplification loop.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [89]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundSingle-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381 · cited 2×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 1×
“AAV exposure can trigger the complement system, an innate defensive mechanism that induces rapid destruction of pathogens and acts as a functional sensor of the surface area of invading particles (17–19).”
BackgroundImmune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · cited 1×
“The activation of the innate and adaptive immunologic responses after de novo exposure to AAV, as well as humoral and cellular responses to pre-existing host immunity, are some of the primary barriers to the expanded use of these therapies (8–10).”
BackgroundSelf-citationCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Self-citationComplement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430 · cited 1×
“The complement system is composed of more than 30 proteins that play important roles in recognition and elimination of pathogens (20).”
BackgroundDifferential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394 · cited 1×
“Importantly, Group 1 showed activation of the complement system, as demonstrated by reduction in C3 and C4, as well as increased C3a, C4a, C5a, Ba, Bb, and SC5b-9 AAV capsid proteins (alternative pathway) (8, 11, 21).”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357 · cited 1×
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · cited 1×
“AAV particles are a potent activator of the innate immune system, not only through the physical properties of the capsid particle, but also through the response to the high capsid protein load associated with systemic AAV administration (11–13).”
BackgroundThe good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286 · cited 1×
“C5b binds to C6, C7, C8, and C9 to generate the soluble C5b-9 (SC5b-9) membrane attack complex (MAC), leading to cell lysis and cell death (17, 24).”
Background
Research works printed but not linked: 3
- Solid Biosciences Provides SGT-001 Program Update [press release]. 2019.
- Pfizer's New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study [press release]. 2020.
- Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease [press release]. 2020.
Cited by
Items 101–163 of 163
The Past, Present, and Future of Cardiac Gene Therapy
Hajjar, R. J. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.035 · Cited by 4
Ren, D., Chauveau, G. A., Cabon, E., Vendomèle, J., Vignal‐Clermont, C., Saliba, H., Ail, D., Dalkara, D., & Fisson, S. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101443 · Cited by 1
Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion
Gwalani, L. A., Park, M., Ysasi, A. B., Motwani, M., Jackson, R., Bu, J., Luo, Z., Bladon, J. H., Pfister, E. L., Mueller, C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.019 · Cited by 1
“72,73 To establish the clinical viability of THOR-834 as an immunomodulatory strategy, a critical next step involves evaluating its efficacy in clinically relevant disease models where immune responses against viral vectors and/or trans-gene products represent well-characterized obstacles to…”
Metagenomic Reconstruction of Adeno-Associated Virus Genomes
Maiakovska, O., Link, L., Zayas, M., Sano, Y., Koay, T. W., Rapti, K., Liu, J., Bubeck, F., Xu, M., Baumgartl, C., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342261419534 · Cited by 1
“88,89 Furthermore, immune responses elicited by an initial AAV application restrict vector redosing.”
Saylam, E., D'Ambrosio, E. S., Pesco, M. T., & Gushchina, L. V. (2026) · Genes · doi:10.3390/genes17030284 · Cited by 1
Meslamani, A. Z. A., Jarab, A. S., & Mohammed, E. M. A. (2026) · Bioanalysis · doi:10.1080/17576180.2026.2638522 · Cited by 1
Bridging science and hope: the evolving story of gene therapy for neuromuscular diseases
Wein, N., & Barthélémy, F. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1765367 · Cited by 1
“Given the association between complement activation and TMA, trials now monitor complement activation as an early indicator of severe immune reactions (Wolff et al., 2025).”
Sensory neuronopathy secondary to gene therapy with AT845 for Pompe disease
Pena-Guzman, L., Bolano-Diaz, C., Lleixà, C., Querol, L., Trainor, C., Suetterlin, K., Straub, V. W., & Díaz‐Manera, J. (2026) · Neuromuscular Disorders · doi:10.1016/j.nmd.2026.106441 · Cited by 1
Lin, N., Mavropoulos, S., & Ishikawa, K. (2026) · Human Gene Therapy · doi:10.1177/10430342261462309 · Cited by 1
“20,21 After reaching target cells, productive AAV entry typically begins with attachment to cell-surface glycans.”
Recent advancements in improving cross-species applicability of bioengineered AAV capsids
Pan, H., Li, N., Qi, J., & Chai, R. (2026) · Gene Therapy · doi:10.1038/s41434-026-00628-y · Cited by 1
“Mice tolerate systemic doses that cause severe hepatotoxicity and DRG degeneration in pigs and NHPs [20], as well as fatal complement activation in humans [79].”
Siddiqui, Z., Neumann, S., Guillen, D., Patel, R., Cox, R., Burnette, W. B., Harris, R., Mohammad, S., & Soslow, J. H. (2026) · Human Gene Therapy · doi:10.1177/10430342261472609 · Cited by 1
Gene Therapy for Hypophosphatasia: Current Management and Future
Matsumoto, T., Narisawa, S., Millán, J. L., & Miyake, K. (2024) · Genetics. · doi:10.5772/intechopen.1006268 · Cited by 1
Keegan, A., Çetin, Ö., Chilcott, E. M., Diaz, J. F. A., Eaton, S. D., Waddington, S. N., Counsell, J. R., Rahman, S., & Karda, R. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201781 · Cited by 1
“54 The CNS-focused delivery strategy employed here is well aligned with the predominant neurological burden in PDHD patients, and ICV AAV delivery is being explored for pediatric neurogenetic disorders (NCT05419492).”
Structural analysis of recombinant AAV vector genomes at single-molecule resolution
Rouleau, D., Lata, D., Dollive, S., Bruccoleri, R. E., van Lieshout, L. P., Golebiowski, D., & Iwuchukwu, I. (2026) · PLoS ONE · doi:10.1371/journal.pone.0339201 · Cited by 1
Gaston, C., Fayard, A., Dufour, N., Hantraye, P., Badin, R. A., & Bemelmans, A. (2025) · Revue de primatologie · doi:10.4000/15jub · Cited by 1
Complement and Complement-Mediated Toxicity
Twardy, S. M., Frazer‐Abel, A. A., & McCullough, R. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00145-5
Keeler, A. M., Flotte, T. R., Blackwood, M., Arjomandnejad, M., Harkins, A. L., Sylvia, K., Iyer, S., Kokoski, D., & Artinian, R. (2025) · Research Square · doi:10.21203/rs.3.rs-6431041/v1
Saliba, H., Gross, D., & Ronzitti, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.007
Therapeutic acute intermittent hypoxia modestly improves breathing in Pompe disease
Roger, A. L., Huston, M. L., Spaulding, M., Metz, C. M., Froeb, R., Wu, R. R., Kehoe, S., Mitchell, G. S., & ElMallah, M. K. (2025) · Respiratory Physiology & Neurobiology · doi:10.1016/j.resp.2025.104489
Pezet, S., Hua, J., Marais, T., Delamare, M., Elouej, S., Lemos, J. P., Castiglione, A., Astord, S., Cohen-Tannoudji, M., Pêche, G. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682744
In Vitro Generation of Brown and Beige Adipocytes via Cellular Reprogramming
Kurahashi, T., Harada, Y., & Dai, P. (2025) · Cellular Reprogramming · doi:10.1177/21524971251399164
“…promoters and AAV serotypes cannot guarantee absolute selectivity, and high-dose AAV has been associated with parenchymal and sinusoidal endothelial injury in the liver (Hordeaux et al., 2024) and with complement-mediated immune events such as thrombotic microangiopathy (Salabarria et al., 2024).”
An AAV-Based Therapy Approach for Neurological Phenotypes of X-Linked Adrenoleukodystrophy
Gornostal, E. A., Alsalloum, A., Degtyarev, E., Kuznetsova, E., Levashova, A., Mishina, D., Mingaleva, N., Mazloum, A., Bogdanov, V. P., Krupinova, J. A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311645
“Thrombotic microangiopathy (TMA) has emerged as another critical, life-threatening adverse event observed at high vector doses [145,146].”
Thomsen, G. M., Kaspar, A. A., Ferraiuolo, L., Chu, B. T. T., Garcia, V. J., Weiss, R., Slaiwa, T. I., Casanova-Vallve, N., Cano, R., Hurley, E., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201707
“31 Additionally, hep-atotoxicity is a known AAV class effect, and acute liver failure and death has been seen across multiple AAV serotypes.”
Preclinical pharmacology and toxicology study of an AAV8-tATP7B vector for Wilson’s disease
Wang, Z., Wang, M., Wu, M., Ye, L., Lou, T., Sun, X., Zhao, W., Liu, F., Ren, T., Li, W., et al. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.1300
Alvisi, M., Roberts, L., Roessig, L., Balderson, D. E., Sanganalmath, S. K., Braun, M., Gordon, S. N., Lacey, S. F., Pandya, P., & Hajjar, R. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261430244 · Cited by 2
“52,53 However, con fi rmation of low or no pre-existing immunity using companion diagnostic tests may not translate to clinical ef fi cacy and safety in AAV GT clinical trials 13 (Table 2).”
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Nishimura, Y., Hataya, S., Saito, S., & Makita, N. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.22.720036
Henry, B. M., Rincón, M. Y., Lippi, G., Prohászka, Z., & Benoit, S. W. (2026) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2887-9935
Gene therapy for aging and longevity
Everts, S. P. A., Florea, M., & de Magalhães, J. P. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.05.007
Yin, L. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016169
Adeno-associated viruses: their impact in the human health and role in the modern healthcare
Ulanova, E. A., & Александровна, Г. В. (2026) · Problems of Virology · doi:10.36233/0507-4088-367
Endothelial injury with capillary leak: A final common pathway in acute AAV toxicity?
Flotte, T. R. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.026
Knapman, F. L., Shklovskaya, E., Swain, R., Turner, A. J., Lovell, N. H., Lisowski, L., Cistulli, P. A., Burke, P. G. R., & Bilston, L. E. (2026) · Research Square · doi:10.21203/rs.3.rs-10146411/v1
Surface-targeted complement modulation at biomedical interfaces
Umnyakova, E. S., Felsch, J., & Ricklin, D. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.06.005
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783.1
Orbach, R., Gil-Garzon, M. R., Büning, H., Bönnemann, C. G., Muntoni, F., Bönnemann, C. G., Büning, H., Assaf, B. T., Beaverson, K., Braun, S., et al. (2026) · Neuromuscular Disorders · doi:10.1016/j.nmd.2026.107371
Self-citationD’Alessandro, R., Somà, A., Vacchetti, M., Salvalaggio, A., Guarnone, E., Cavallina, I., Rolle, E., Rossi, F., Montin, D., Saglio, F., et al. (2026) · Neuromuscular Disorders · doi:10.1016/j.nmd.2026.107376
Wagenmakers, M., Lehman, A., den Hoed, C. M., van Dussen, L., Langeveld, M., & Sirrs, S. M. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04377-4
“Throm-botic microangiopathy and dorsal root ganglion injury are other immune-mediated injuries reported after AAV GTMP [47, 48].”
Wang, Y., Kong, Z., Zhao, Y., Pei, B., Sun, J., Mao, X., Gong, W., Chen, Y., Yin, R., Cao, M., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117277 · Cited by 1
Kong, Z., Wang, Y., Zhao, Y., Wang, L., Fan, Z., Shu, Y., & Wang, J. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70804 · Cited by 1
“58 Moreover, several FDA-approved agents—such as antibodies targeting the neonatal Fc receptor (FcRn), IgG-cleaving endopeptidase, and IgG-degrading enzymes—have shown efficacy in reducing or eliminating anti-AAV antibodies, including neutralizing antibodies (NAbs), 59–63 thereby supporting…”
Horita, K., Miyauchi, R., Yamamoto, H., Yamazaki, Y., Nagatomo, K., Aburatani, T., Takeda, S., & Baba, S. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201838
Clinical immunogenicity in rAAV gene therapy: Insights and implications
Gulve, N., Bego, M. G., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201848 · Cited by 1
“60 The immune-related clinical observations that have been typically observed as rAAV-associated adverse events are discussed in the next section with primary emphasis on the underlying pathology, the target therapeutic indication, underlying causative immune mechanisms, diagnostic considerations,…”
Lai, C., Irvin, S. C., Salazar‐Fontana, L. I., Grimaldi, C., Gorovits, B., Xu, Y., & Partridge, M. A. K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01303-1 · Cited by 1
“…anti-AAV antibodies may still benefit from a GTP treatment, especially with locally administered GTPs (17, 67–69) and, furthermore, prophylactic immunosuppressive regimens may be sufficient to mitigate early safety signals such as complement-mediated toxicity for single dose treat-ment (70).”
Yu, Z., Li, Y., Zhang, Z., & Yin, R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1901875
“…injury are additional concerns: systemic AAV9 has been associated with anti-capsid-antibody-dependent thrombotic microangiopathy and complement activation, while liver injury has been observed after both intravenous and intrathecal scAAV9 delivery (Hudry et al., 2023; Salabarria et al., 2024).”
Lee, C., Chuang, C., Chang, Y.-H., Chiu, H., Tu, Y.-R., Lo, Y., Wu, J., Huang, H.-Y., Lin, H. Y., & Lin, S.-P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188270
“These are relevant development risks for both AAV-TAZ and AAV-FXN, rather than an FXN-specific limitation [71].”
Feller, C., Young, S. C., & Gupta, K. (2026) · Human Gene Therapy · doi:10.1177/10430342261488959
Systemic responses to intravenous rAAV administration in boys with Duchenne muscular dystrophy
Harris, B. E., Seldin, B. M., Towne, S. C., Hobson, O. R., Zerpa, E., Prima, V., Sweeney, H. L., & Hammers, D. W. (2026) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2026.1953867
IPNA clinical practice recommendations for the management of aHUS and secondary TMA in children
Khursigara, M. R., Alconcher, L. F., Alhasan, K. A., Awan, A., Bagga, A., Bashir, A., Boyer, O., Bresolin, N. L., Coccia, P. A., Durkan, A., et al. (2026) · Pediatric Nephrology · doi:10.1007/s00467-026-07537-7 · Cited by 2
Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease
Cetin, B., Aliciaslan, M., Erbasan, E., Cesur, B., & Şanlıoğlu, S. (2026) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2026.10072
“83).”
Tate, G. R., McNulty, J., Widrick, J. J., & Gupta, V. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.23.753846
Argirò, A., & Olivotto, I. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2026.26
Xu, Z., Luo, X., Li, Y., Qian, J., & Xu, G. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1949512
“…et al., 2023; Gonzalez-Gil and Schnaar, 2021) Complement regulation by sialic acid/ factor H Established (Ricklin et al., 2010; Kropf et al., 2024; Salabarria et al., 2024; Benemei et al., 2024; Zaiss et al., 2008) MMP-, pH-and GSH-responsive elements (individually) Established (non-viral…”
Ding, Q., Zhou, X., Olson, E. N., & Liu, N. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107709
Reframing liver test abnormalities after AAV gene therapy: a mechanistic diagnostic framework
Henry, B. M., Bénichou, B., Rincón, M. Y., Lippi, G., & D’Antiga, L. (2026) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2026.111217
Braun, M., Ravesteijn-Verrijt, C., Schatz, P., Lu, Y., Seninet, S., Giblin, J., Millholland, J. M., Chichili, G. R., McBlane, F., Stanta, J. L., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201862
Mathiesen, S. (2025) · Otago University Research Archive (University of Otago)
Stage-specific Therapy for Muscular Dystrophies: From Care Standards to Gene and RNA Medicines
Choudhary, A., Kuriyal, S., chowdhury, P. H., & Baladaniya, M. (2026) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.1177/0976500x261493196
Caragiulo, A., Rosenberg, J. B., De, B. P., Kaminsky, S. M., Martin, H. R., Butler, S. J., Rodó, J., Sondhi, D., Strulovici, Y., & Crystal, R. G. (2026) · Human Gene Therapy · doi:10.1177/10430342261495296
CNS targeted AAV gene therapies: Recent advances and clinical insights
Brown, B. P., Lewis, R. W., Jr., & Davidson, B. L. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103118 · Cited by 1
Corti, S. P., Ottoboni, L., Beatrice, F., D’Angelo, A., Marcotti, F., D'Agostino, M., Rizzo, F., Magni, G., & Comi, G. P. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107661
Zhang, N., Ting, M. H., Liu, S., Jiao, X., Li, X., Wang, P., Fu, G., Li, H., Ge, J., Sun, Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-79082-8
Metadata
- Authors
- Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., Leon-Astudillo, C., Tavakkoli, F., Kirn, D. H., Schwartz, J. D., & Byrne, B. J.
- Affiliations
- University of Florida Health (US)
- National Institutes of Health (US)
- Indiana University South Bend (US)
- Corresponding author
- Byrne, Barry J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2024-01-02
- Volume
- 134
- Issue
- 1
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10760971
- OpenAlex
- W4388860142
- Cited by
- 159
- References
- 35
- Citations by year
- 2026: 59 · 2025: 55 · 2024: 44
- FWCI
- 26.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- College of Medicine, University of Florida (HD052682)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- thrombotic microangiopathy, AAV9, AAV gene therapy, complement activation, classical complement pathway, alternative complement pathway, rituximab, rapamycin, corticosteroids, immunomodulation, D-dimer, atypical hemolytic uremic syndrome, immune-mediated toxicity
- MeSH terms
- Dependovirus, Humans, Immunoglobulin G, Immunoglobulin M, Thrombotic Microangiopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.